Clinical Report: Can Endotoxin-Targeted Care Improve Sepsis Outcomes?

Overview

The TIGRIS trial indicates that endotoxin activity-guided patient selection may enhance the efficacy of polymyxin B hemoperfusion in sepsis with reversible organ dysfunction. This approach is based on the trial's focus on a specific patient population, contrasting with previous trials that enrolled biologically heterogeneous populations.

Background

Sepsis remains a critical global health issue, significantly impacting morbidity and mortality rates in intensive care settings. The evolution of sepsis definitions highlights the complexity of the condition and the need for targeted therapeutic approaches.

Data Highlights

No numerical data available in the provided source material.

Key Findings

• The TIGRIS trial focused on patients with endotoxin activity assay values of 0.60 to 0.89 and significant organ dysfunction.
• Biologically guided patient selection may improve outcomes compared to syndromic enrollment, though these findings are preliminary.
• The endotoxin activity assay measures circulating endotoxin bioactivity, showing variability among patients.
• Future studies could benefit from incorporating biomarker-guided enrollment and adaptive trial designs.
• Preliminary evidence from the TIGRIS trial suggests potential benefits of endotoxin-targeted therapy, but further validation is needed.

Clinical Implications

The findings from the TIGRIS trial suggest that utilizing endotoxin activity assays for patient selection may enhance the effectiveness of treatments like polymyxin B hemoperfusion. Further research is necessary to determine the feasibility of broader implementation.

Conclusion

The TIGRIS trial highlights the importance of biomarker-guided therapeutic approaches in sepsis management. Further research is necessary to validate these preliminary findings.

Related Resources & Content

1. Iba T., Journal of Anesthesia, Analgesia and Critical Care, 2023 -- Can Endotoxin-Targeted Care Improve Sepsis Outcomes?
2. Critical Care (Springer) — Clinical applications for the endotoxin activity assay in sepsis: a scoping review
3. Critical Care (Springer) — Predictive enrichment using biomarkers in studies of critically-ill patients with sepsis: a systematic review
4. Intensive Care Medicine — Endotype trajectories: better understanding for better sepsis management
5. Infection — The evolution of sepsis care: from protocol-driven management to personalized intensive care
6. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026
7. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial
8. Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial
9. https://www.jaam.jp/info/2024/files/J-SSCG2024_CQ4-6.pdf
10. The role of polymyxin B-immobilized hemoperfusion in reducing mortality and enhancing hemodynamics in patients with sepsis and septic shock: A systematic review and meta-analysis - PMC
11. Blood Purification for Adult Patients With Severe Infection or Sepsis/Septic Shock: A Network Meta-Analysis of Randomized Controlled Trials - PubMed
12. Current clinical practice in using adjunctive extracorporeal blood purification in sepsis and septic shock: results from the ESICM “EXPLORATION” survey - PMC